 |
 |
| Home |
| Clinical Trial Search |
| Mailing List |
| Clinical Trial FAQs |
| Participation FAQs |
| Clinical Trials Glossary |
| About Informed Consent |
| Medical Research Areas |
| Clinical Trial Links |
| How to use this System |
|
This site is intended for U.S. residents only. For Novartis Worldwide, Click here |
|
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
|
|
|
|
|||
Clinical Trial Search
Cryopyrin-Associated Periodic Syndromes (CAPS)
Cryopyrin-associated periodic syndromes (CAPS) are autosomal-dominant autoinflammatory disorders, including chronic infantile neurological cutaneous articular (CINCA) syndrome, also known as neonatal-onset multisystem inflammatory disease (NOMID), Muckle–Wells syndrome (MWS) and familial cold autoinflammatory syndrome (FCAS). CINCA syndrome is a severe chronic inflammatory disease, characterized by the neonatal onset of cutaneous symptoms, chronic meningitis and joint manifestations, with recurrent fever and inflammation, while MWS is characterized by the classical triad of deafness, rashes, swollen and painful joints, and FCAS manifests as skin lesions after exposure to cold. [Source: http://rheumatology.oxfordjournals.org]
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Cryopyrin-associated periodic syndromes (CAPS) Study CACZ885D2306
The purpose of this clinical research trial is to find out if the study drug ACZ885 is safe and will effectively reduce signs of inflammation (such as redness, swelling, pain and fever) in participants who have been diagnosed with the following Cryopyrin-associated periodic syndromes: Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS) or Muckle-Wells Syndrome with overlapping symptoms of Neonatal Onset Multisystem Inflammatory Disease (NOMID). This study drug is not approved by the FDA for treatment of people with your disease and is NOT available for sale in the U.S.
Trial phase: Phase 3 Participation Duration: Participants will be required to visit the study center for treatment every 8 weeks. The minimum treatment duration will be 6 months and the maximum treatment duration will be 2 years. Protocol Number: CACZ885D2306 |
